Single-center retrospective study links subcutaneous trastuzumab to higher complete-response odds in HER2-positive breast cancer
A retrospective cohort of 450 East Asian patients with HER2-positive breast cancer found that subcutaneous neoadjuvant trastuzumab was associated with ...
